Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms

INTRODUCTION: Imipenem/cilastatin/relebactam (IMI/REL), a combination β-lactam antibiotic (imipenem) with a novel β-lactamase inhibitor (relebactam), is an efficacious and well-tolerated option for the treatment of hospitalized patients with gram-negative (GN) bacterial infections caused by carbapen...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Joe, Naik, Jaesh, Massello, Matthew, Ralph, Lewis, Dillon, Ryan James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334485/
https://www.ncbi.nlm.nih.gov/pubmed/35334080
http://dx.doi.org/10.1007/s40121-022-00607-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334485/
https://www.ncbi.nlm.nih.gov/pubmed/35334080
http://dx.doi.org/10.1007/s40121-022-00607-x

Ejemplares similares